Biogen Inc BIIB:NASDAQ (Common Stock)

LastChange / % ChangeDividend YieldVolumeAvg Volume (10 day)
398.68 -2.47   -0.62%829,8401.2M
Market data is delayed by at least 20 minutes.
Summary chart showing the current equity's performance of over the past 1 days
  • Advanced Charts
  • Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

Market is closed. Chart as of 03:59 PM ET 5/22/2015

Latest News Headlines for Biogen Inc

Biogen to Present at Bernstein's 31(st) Annual Strategic Decisions Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 20, 2015-- Biogen Inc. (NASDAQ: BIIB) announced today that it will present at Bernstein's 31(st) Annual Strategic Decisions Conference. The webcast will be live on Wednesday, May 27, 2015 at 2:00 p.m. ET. To access the live webcast, please visit Biogen's Investors section at www.biogen.com. An archived version of the webcast will be available for 14 days following the presentation.

Biogen to Present at the 2015 UBS Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 13, 2015-- Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the 2015 UBS Global Healthcare Conference. The webcast will be live on Tuesday, May 19, 2015 at 1:00p.m. ET. To access the live webcast, please visit Biogen's Investors section at www.biogen.com. An archived version of the webcast will be available for 14 days following the presentation.

Biogen Names Matt Griffiths as Chief Information Officer

Former Dell Executive to Advance Biogen's Focus on Technology, Data and Devices CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 13, 2015-- Biogen (NASDAQ: BIIB) announced today the appointment of Matt Griffiths as senior vice president and chief information officer (CIO). He will report to the company's executive vice president of Technology and Business Solutions, Adriana Karaboutis. Mr. Griffiths was promoted to the CIO role from his position as vice president of Pharmaceutical Operations and Corporate Information Technology, having joined Biogen from Dell earlier this year.

View more recent headlines

Peers Information HelpBIIB Biogen Inc vs. Peers

BIIB
Biogen Inc
18.18%
-2.06%
Johnson & Johnson
Pfizer Inc.
10.30%
Merck & Co., Inc.
5.83%
AbbVie Inc
0.32%
BIIB
Biogen Inc
0.00%
Johnson & Johnson
2.96%
Pfizer Inc.
3.27%
Merck & Co., Inc.
3.03%
AbbVie Inc
3.12%
-0.62%
BIIB
Biogen Inc
-1.04%
Johnson & Johnson
-0.23%
Pfizer Inc.
-1.20%
Merck & Co., Inc.
-0.26%
AbbVie Inc
Compare these stocks

Latest Annual and Quarterly SEC Filings

More Filings
10-K

This report contains detailed information about the company's business finances and management.

10-Q

Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)

Company Background

Biogen Inc., formerly Biogen Idec Inc., is a global biotechnology company. The Company discovers, develops, manufactures and markets therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. The Company’s products include AVONEX, TYSABRI, FAMPYRA, FUMADERM and RITUXAN. AVONEX is prescribed treatments for relapsing forms of multiple sclerosis (MS). AVONEX is a recombinant form of the interferon beta protein produced in the body in response to viral infection. TYSABRI is a monoclonal antibody approved in numerous countries as a monotherapy treatment for relapsing MS and to treat Crohn’s disease. The Company’s RITUXAN is a monoclonal antibody therapeutic used to treat non-Hodgkin’s lymphoma, rheumatoid arthritis, chronic lymphocytic leukemia among others. FAMPYRA addresses the need of walking improvement in adult patients with MS who have walking disability and for the treatment of psoriasis.

https://www.biogen.com/

Loading...

collapse, right-facing arrow indicating collapsed view of sectionOverview

A table providing an overview of the stock
Bid | Size-- | --
Ask | Size-- | --
Price Open399.19
Previous Close401.15
Day High401.7899
Day Low397.40
52 Week High3/20/2015 | 480.18
52 Week Low10/22/2014 | 290.85
% Off 52 Week High-16.97%
% Off 52 Week Low37.07%
Beta (5 Yr)1.0
Volatility Avg5/22/2015 | 33.86
10-Day Avg. Volume1,245,478
Market data is delayed by at least 20 minutes.

expand, down-facing arrow indicating expanded view of sectionFundamentals

A table providing the fundamentals of the stock
EPS (TTM)3/31/2015 | 13.85
P/E Ratio3/31/2015 | 29.0
Market CapLarge Cap | 93.8B
Shares Outstanding235.23M
Float235.0M

collapse, right-facing arrow indicating collapsed view of sectionDividends

A table providing information about the dividends of the stock
Dividend Yield--
Ex-Date--
Dividend Announcement--
Date of Record--
Payable-- - --
Payable Date--

collapse, right-facing arrow indicating collapsed view of sectionShare Statistics

A table providing statistics about shares of the stock
Shares Short2.98M
Short Ratio1.1
Short % of Float1.27%
As of 4/30/2015